

or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.3% to about 50% of the first component.

REMARKS

Claims 12-29 are currently pending. Claims 12, 20, 26, and 27 have been amended to correct the printing error that occurred in the structural formula of formula I. Specifically, the cyano group that is alpha to the carbonyl moiety did not print correctly in the July 15, 1998 preliminary amendment. Support for this amendment can be found

B3


LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L. L. P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

SECRET

It is believed that there are no additional fees due in connection with the filing of this response. However, if any such fees are due, including any fee for extension of time, the Commissioner is hereby authorized to charge such fees to our Deposit Account No. 06-916.

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.



Allen Jensen
Reg. No. 28,224

Dated: August 17, 1998